Monopar Therapeutics stockholders elect six directors and ratify BPM LLP as auditor at 2023 annual meeting

Monopar Therapeutics

All six director nominees elected with >8.7M for votes each; broker non-votes ~1.65M.
Ratification of BPM LLP as independent auditor passed with 10,529,760 for, 3,071 against.
Total shares represented 10,561,932 out of 13,222,055 entitled, ~80% turnout.
No other matters were submitted to a vote at the meeting.
Directors include Starr, Robinson, Brown, Anderson, Klausner, Tsuchimoto.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Monopar Therapeutics shareholders approved Ratification of selection of BPM LLP as independent registered public accounting firm for year ending December 31, 2023 at the 2023-06-27 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-27

Exact text from the filing

Proposal 2 – Ratification of Selection of Independent Registered Public Accounting Firm The voting results with respect to the proposal to ratify the selection of BPM LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2023, were as follows: For Against Abstain Broker Non- Votes 10,529,760.056 3,071.000 29,101.000 N/A Accordingly, the Company’s stockholders ratified the selection of BPM LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2023.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Monopar Therapeutics shareholders approved Election of six directors at the 2023-06-27 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-27

Exact text from the filing

Proposal 1 – Election of Directors At the Annual Meeting, the voting results with respect to the proposal for the election of directors, included in the Company’s Proxy Statement on Schedule 14A for the Annual Meeting, were as follows: Director For Withheld Broker Non- Votes Christopher M. Starr, Ph.D. 8,821,107.056 89,311.000 1,651,514.000 Chandler D. Robinson, MD MBA MSc 8,824,034.056 86,384.000 1,651,514.000 Michael J. Brown, MSc 8,822,931.056 87,487.000 1,651,514.000 Raymond W. Anderson, MBA 8,822,724.056 87,694.000 1,651,514.000 Arthur J. Klausner, MBA 8,785,520.056 124,898.000 1,651,514.000 Kim R. Tsuchimoto 8,820,687.056 89,731.000 1,651,514.000 Accordingly, each of the foregoing persons was elected as a director at the Annual Meeting.

View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001437749-23-018753

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.